Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis
about
Mycobacteria and the new quinolonesComparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacinEarly anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis.Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosisPharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Adapting therapy with repeated short-infusions to inter individual variability between patients.Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal.Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones.Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis.Pharmacokinetics of ciprofloxacin with reference to other fluorinated quinolones.Clinical pharmacokinetics of inhaled antimicrobials.Clinical utility of new quinolones in treatment of osteomyelitis and lower respiratory tract infections.The 4-quinolone antibiotics: past, present, and future.Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients.Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia.Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study.Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis.Calculation of the antibiotic level in the lung tissue and bronchial secretion with an oral controlled-release dosage form.
P2860
Q28342507-D9D1BAFF-67A3-4751-8543-985E0F1B4B79Q28378625-66E5F560-F623-4D7B-BF13-7B8A67A9142EQ30436229-868FD52F-A3C2-4BD9-BB90-094E7ED09EB0Q33975978-36E6CEE9-9828-4022-8691-D0095B7C08C5Q33983611-7F655E65-B1E6-4276-9EC7-AC5FE7645457Q34297656-5FECE8CE-D6AC-4018-9C98-C13EFD9674E4Q36911758-0F488F6D-3F8F-4E9F-A211-63F744C9B37FQ37347003-37A36F52-D3B1-4DD3-9457-63275881E2A5Q38040734-1383E882-6D73-4471-A5E4-6BBCD55EBCBFQ38108277-BDEB2573-A9F3-4104-9DAD-76DAF4DEB96AQ38271416-2E7FB1EC-25B7-49A9-9924-A6B136F8B114Q38367260-B72DAFE9-A303-41FE-8ED6-F691B045AB4FQ38765037-4BB713A0-12B1-4CD0-96FF-31AA0C75BD1FQ39314610-14BC5F56-C045-40CB-8E8D-5DF194AE7A08Q40284573-BDC94DAF-5351-4920-9400-6AE3B095A205Q40285699-67913166-01A7-48F5-95E0-B8C32805F7DAQ41071899-ACE87234-2B41-46DD-8C50-156A668C2ADBQ44023516-DB0B3432-7D27-40AB-993D-C268FB739442Q50949982-AB493C1C-25CA-4EB1-AE45-908CD46B05B9
P2860
Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
1986年论文
@zh
1986年论文
@zh-cn
name
Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis
@ast
Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis
@en
type
label
Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis
@ast
Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis
@en
prefLabel
Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis
@ast
Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis
@en
P2093
P2860
P356
P1476
Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis
@en
P2093
P2860
P304
P356
10.1128/AAC.30.4.614
P407
P577
1986-10-01T00:00:00Z